Open access · CC-BY
via OpenAlex
Activation of telomerase by TA-65 enhances immunity and reduces inflammation post myocardial infarction
Bilal Bawamia, Luke Spray, Vincent Kharisma Wangsaputra, Karim Bennaceur, Sharareh Vahabi, Konstantinos Stellos, Ehsan Kharatikoopaei, Emmanuel Olusegun Ogundimu, Chris P Gale, Bernard D. Keavney, Rebecca H. Maier, Helen C. Hancock, Gavin David Richardson, David Austin, Ioakim Spyridopoulos
GeroScience · 2023 · ▲ 29 citations
Abstract
Abstract Myocardial infarction (MI) accelerates immune ageing characterised by lymphopenia, expansion of terminally differentiated CD8+ T-lymphocytes (CD8+ TEMRA) and inflammation. Pre-clinical data showed that TA-65, an oral telomerase activator, reduced immune ageing and inflammation after MI. We conducted a double blinded randomised controlled pilot trial evaluating the use of TA-65 to reduce immune cell ageing in patients following MI. Ninety MI patients aged over 65 years were randomised to either TA-65 (16 mg daily) or placebo for 12 months. Peripheral blood leucocytes were analysed by flow cytometry. The pre-defined primary endpoint was the proportion of CD8+ T-lymphocytes which were CD8+ TEMRA after 12 months. Secondary outcomes included high-sensitivity C-reactive protein (hsCRP) levels. Median age of participants was 71 years. Proportions of CD8+ TEMRA did not differ after 12 months between treatment groups. There was a significant increase in mean total lymphocyte count in the TA-65 group after 12 months (estimated treatment effect: + 285 cells/μl (95% CI: 117–452 cells/ μ l, p < 0.004), driven by significant increases from baseline in CD3+, CD4+, and CD8+ T-lymphocytes, B-lymphocytes and natural killer cells. No increase in lymphocyte populations was seen in the placebo group. At 12 months, hsCRP was 62% lower in the TA-65 group compared to placebo (1.1 vs. 2.9 mg/L). Patients in the TA-65 arm experienced significantly fewer adverse events (130 vs. 185, p = 0.002). TA-65 did not alter CD8+ TEMRA but increased all major lymphocyte subsets and reduced hsCRP in elderly patients with MI after 12 months.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1007/s11357-023-00794-6
- Canonical
- link ↗
- Fetched
- 2026-10-31 MST
Cite this
APA
Bawamia, B., Spray, L., Wangsaputra, V.K., Bennaceur, K., Vahabi, S., Stellos, K., Kharatikoopaei, E., Ogundimu, E.O., Gale, C.P., Keavney, B.D., Maier, R.H., Hancock, H.C., Richardson, G.D., Austin, D., & Spyridopoulos, I. (2023). Activation of telomerase by TA-65 enhances immunity and reduces inflammation post myocardial infarction. <em>GeroScience</em>. https://doi.org/10.1007/s11357-023-00794-6
Vancouver
Bawamia B, Spray L, Wangsaputra VK, Bennaceur K, Vahabi S, Stellos K, et al. Activation of telomerase by TA-65 enhances immunity and reduces inflammation post myocardial infarction. GeroScience. 2023. doi:10.1007/s11357-023-00794-6.
BibTeX
@article{bilal2023Activa,
title = {Activation of telomerase by TA-65 enhances immunity and reduces inflammation post myocardial infarction},
author = {Bilal Bawamia and Luke Spray and Vincent Kharisma Wangsaputra and Karim Bennaceur and Sharareh Vahabi and Konstantinos Stellos and Ehsan Kharatikoopaei and Emmanuel Olusegun Ogundimu and Chris P Gale and Bernard D. Keavney and Rebecca H. Maier and Helen C. Hancock and Gavin David Richardson and David Austin and Ioakim Spyridopoulos},
journal = {GeroScience},
year = {2023},
doi = {10.1007/s11357-023-00794-6},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Newcastle University ePrints (Newcastle Univesity) 2023
Preprint · CC-BY
Activation of telomerase by TA-65 enhances immunity and reduces inflammation post myocardial infarction Randomized Pilot Trial
Frontiers in Physiology 2019
Open access · CC-BY
Stress Related Shift Toward Inflammaging in Cosmonauts After Long-Duration Space Flight
Advanced Science 2022
Open access · CC-BY
Single‐Cell Transcriptomics Reveals Longevity Immune Remodeling Features Shared by Centenarians and Their Offspring
Respiratory Research 2014
Open access · CC-BY
Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study
Sanofi Pasteur, a Sanofi Company 2007
Open access · US-GOV
Evaluation of the Cellular, Humoral and Mucosal Immune Response in Adults and Elderly Subjects Vaccinated Either With an Inactivated Influenza Vaccine Administered Via the Intradermal Route or an Inactivated Influenza Vaccine Administered Via the Intramuscular Route
The Journal of Immunology 2000
Citation only